A peripherally restricted P2Y(12) receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism

BACKGROUND: Ticagrelor is an orally available, direct acting and reversible P2Y(12) receptor antagonist approved for treatment of acute coronary syndrome. The objectives of these studies were to (1) evaluate the Ticagrelor 2-year rat carcinogenicity bioassay data; (2) investigate potential mode of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brott, David A., Andersson, Håkan A.S., Stewart, Jane, Ewart, Lorna, Christoph, Greg, Harleman, Johannes, Armstrong, Duncan, Kinter, Lewis B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598522/
https://www.ncbi.nlm.nih.gov/pubmed/28962330
http://dx.doi.org/10.1016/j.toxrep.2014.11.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598522/
https://www.ncbi.nlm.nih.gov/pubmed/28962330
http://dx.doi.org/10.1016/j.toxrep.2014.11.010

Ejemplares similares